Browse studies

Find your next paid study

47 recruiting studies matching your filters

A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Upadacitinib in Pediatric Subjects With Severe Alopecia Areata

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the scalp and face, but h…

Severe Alopecia Areata

A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2/3 Study to Assess Efficacy and Long-Term Safety of PP405 in Adult Males With Androgenetic Alopecia

The study is designed to validate efficacy and long term safety of PP405.

Androgenetic Alopecia

Estimated

~$10 – $8,750

Pelage Pharmaceuticals, Inc.NCT07819435

Observational

A Pilot Study Evaluating the Safety and Efficacy of a 1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia

Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and sc…

Scarring AlopeciaAndrogenetic Alopecia

Estimated

~$10 – $6,250

Montefiore Medical CenterNCT05460611

Phase 2

Tirzepatide for Treatment of CCCA

The goal of this pilot clinical trial is to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring…

Central Centrifugal Cicatricial Alopecia (CCCA)

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07734870

Phase 2

A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata

The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo, and how w…

Alopecia Areata

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07533006

Phase 3

A PHASE 3, EXTERNAL AND SYNTHETIC PLACEBO-CONTROLLED RANDOMIZED STUDY WITH DOSE-UP FOR NON-RESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA

The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia ar…

A Phase 1 Study of HCW9302, an IL-2 Fusion Protein, for Alopecia Areata

This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)

Alopecia Areata(AA)

Estimated

~$10 – $7,500

HCW BiologicsNCT07049328

Phase 3

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE ALOPECIA AREATA

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the potential treatment of moderate…

An Observational Study of Patients With Dermatologic Disease

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who tre…

VitiligoAtopic DermatitisAlopecia Areata+1 more

Estimated

~$10 – $1,050

Target PharmaSolutions, Inc.NCT07748169

Observational

A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia.

Central centrifugal cicatricial alopecia (CCCA) is form of scarring hair loss that predominately affects middle-aged women of African descent.1 . Clinically, t…

Central Centrifugal Cicatricial Alopecia

Estimated

~$10 – $6,250

Wake Forest University Health SciencesNCT04764331

Observational

Dual Modality Treatment of Androgenic Alopecia With KeraFactor® Solution and Revian® LED Light Therapy: A Randomized, Placebo Controlled Study

This single-center, prospective, randomized, placebo-controlled interventional study will evaluate the safety and efficacy of KeraFactor scalp-stimulating solu…

Androgenic AlopeciaFemale Pattern Hair LossHair Loss

Estimated

~$10 – $8,750

K. Kay Durairaj, MD, FACS, A Medical CorporationNCT07810504

Phase 3

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in…

Areata AlopeciaAlopeciaHypotrichosis+3 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT05723198